Top

Published in:

01-05-2018 | Rebuttal Letter

Reply to K. Altundag

Authors: E. A. Underwood, M. C. Tierney

Published in: Breast Cancer Research and Treatment | Issue 1/2018

Excerpt

We thank Dr. Altundag for his comments on our recent meta-analysis [1]. In his Letter, Dr. Altundag rightly points out that chemotherapy exposure in breast cancer control groups could affect cognitive functioning in these patients. We recognized this and did, in fact, take chemotherapy exposure into account in our meta-analysis. …

Underwood EA, Rochon PA, Moineddin R, Lee PE, Wu W, Pritchard KI, Tierney MC (2017) Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-017-4627-4 PubMed

Vitali M, Ripamonti CI, Roila F, Proto C, Signorelli D, Imbimbo M, Corrao G, Brissa A, Rosaria G, de Braud F, Garassino MC, Lo Russo G Cognitive impairment and chemotherapy: a brief overview. Crit. Rev. Oncol/Hematol 118:7–14. https://doi.org/10.1016/j.critrevonc.2017.08.001

Title: Reply to K. Altundag
Authors: E. A. Underwood
M. C. Tierney
Publication date: 01-05-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4703-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

Is invasion a necessary step for metastases in breast cancer?

Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial

Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence

Detailed information about chemotherapy in breast control arm might affect cognitive sequelae compared with endocrine therapy patients

Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I–III breast cancer: ER+/PR+, HER2- vs. triple-negative

Impact of an embedded genetic counselor on breast cancer treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer